Finally, we found two fibroblast subtypes (Fib_Apoc1+/Fabp4+ and inflam-Fib1) and the Trem2+ macrophage subtype, that may be effective cellular targets for the treatment of AAA. Here, FABP4 is linked to triple-A syndrome.